1.Validity analysis of pulmicort respulas combined with montelukast in treating children with asthma and its role in pulmonary function and T lymphocyte subset
Drug Evaluation Research 2017;40(3):377-380
Objective To explore the validity of oxygen atomizing inhalation pulmicort respulas combined with montelukast in treating children with asthma and its role in pulmonary function and T lymphocyte subset.Methods Totally 78 cases treated in Huizhou People's Hospital from June,2014 to June,2016 were randomly divided into observation group and control group with each group of 39 cases.The control group on the basis of routine treatment with oxygen atomizing inhalation of pulmicort 1 mg,twice daily,and the observation group based on control group added Montelukast Sodium Chewable Tablets 5 mg,once daily,one week for one course.The clinical effect,pulmonary function,and level of T lymphocyte subset were compared between two groups.Results The total effective rate in the observation group was 94.70%,which was significantly higher than control group (82.05%,P < 0.05).After therapy,the symptom scores of two groups were obviously decreased compared with those before therapy (P < 0.05),and those of the observation group were significantly lower than control group (P < 0.05);The pulmonary function of the two groups were obviously improved (P < 0.05) compared with that before therapy (P < 0.05),and the levels of FEV1,FVC,and FEV1/FVC in observation group were significantly higher than control group (P < 0.05);The level ofT lymphocyte subset in control group showed no statistical difference compared to that before therapy,and the levels of CD4+ and CD4+/CD8+ in observation group were obviously decreased,whereas CD8+ was increased.Conclusion Oxygen atomizing inhalation pulmicort respulas combined with montelukast could effectively increase the clinical effect on children with asthma,improve pulmonary function and positively regulate immune function,which deserves clinical expansion.
2.Clinical effects of ganciclovir combined with gangliosides and gamma globulin in treating children with viral encephalitis
Songyi GAO ; Qinghua DANG ; Xiaoqian GAO ; Yan SUN ; Wenjing ZHAO
Drug Evaluation Research 2017;40(3):373-376
Objective To compare the clinical effect and safety evaluation of three different dose regimens for treating children with viral encephalitis.Methods Totally 126 cases treated in Xi'an Central Hospital from January 2010 to December 2015 were randomly divided into observation group 1 (ganciclovir combined with gangliosides,42 cases),observation group 2 (ganciclovir combined with gamma globulin,43 cases),and control group (39 cases).The clinical effect and levels of NSE,inflammatory cytokine were compared in the three groups.Results The total effective rate in observation group 1 was 95.24% and that of observation group 2 was 93.02%,which were significantly higher than that of control group (79.48%).The disappearance time of headache,fever,convulsions,clouding of consciousness,meningeal irritation sign,cerebrospinal fluid abnormalities,and length of stay in observation groups (both 1 and 2)were significantly shorter than those in control group (P < 0.05);After therapy,the levels of NSE in three groups were obviously decreased compared with those before therapy (P < 0.05),and those in observation group were significantly lower than the control group (P < 0.05);the levels of inflammatory cytokine in all three groups were obviously decreased compared with those before therapy (P < 0.05),and that of observation group 1 had no statistical difference with the normal group,whereas that in control group was significantly higher than the normal group (P < 0.05).Conclusion Ganciclovir combined with gangliosides as well as ganciclovir combined with gamma globulin were both effective methods in treating children with viral encephalitis and could decrease levels of inflammatory cytokine.Ganciclovir combined with gangliosides could effectively repair nerve damage,which deserves clinical expansion.
3.Effect of rivaroxaban in preventing deep venous thrombosis after large orthopedic operation of lower extremity
Drug Evaluation Research 2017;40(3):369-372
Objective To discuss the effect ofrivaroxaban in preventing deep venous thrombosis after large orthopedic operation of lower extremity.Methods Totally 80 patients after lower extremity of large orthopedic operation were selected,they were divided into two groups randomly.The patients in control group (39 cases) were sc injected with enoxaparin through.The patients in observation group (41 cases) were given rivaroxaban orally.The effect of rivaroxaban in preventing deep venous thrombosis after large orthopedic operation of lower extremity were evaluated by hemodynamic indexes,diagnosis index,and complications during 1 months follow-up.Results Before operation,there was no statistical significance on platelet,hemoglobin,and PT values between two groups.Compared with the value before operation,the value ofplatelet and hemoglobin had no significantly change after 3 d of operation.But the PT was increased (P < 0.05).After 3 d of operation,there was no statistical significance on platelet and hemoglobin between two groups.But the PT value of observation was higher than that of control group (P < 0.05).After 1 h operation,there was no statistical significance on D-dimer,Hcy,and hs-CRP between two groups.Compared with the value after 1 h of operation,the values of D-dimer,Hcy,and hs-CRP were decreased significantly (P < 0.05).And the indexes of observation group were lower than those of control group (P < 0.05).After 1 months of operation,although there was no statistical significance on complications between two groups,the incidence rate of secondary bleeding and DVT of control group was higher than that of the observation group.Conclusion The rivaroxaban could prevent DVT well,which is suitable for the anticoagulation therapy after lower extremity of large orthopedic operation with little influence on platelet and hemoglobin.It is worthy of clinical application.
4.Research progress on pharmacologic action of Atractylodis Rhizoma and its effective constituent in in digestive system
Drug Evaluation Research 2017;40(3):411-419
The pharmacologic action of Atractylodis Rhizoma and its effective constituents in digestive system includes mainly anti-ulcer activity,acceleration of gastric emptying,regulation of gastrointestinal propellant movement,antidiarrheat effect,choleretic effect,hepatoprotection,and promotion of digestive and absorptive function.Atractylodis Rhizoma decreases gastric acid secretion via blockade of H2-receptor,and inhibits overexpression of inflammatory cytokines in gastric tissues to produce anti-ulcer effect.Atractylodis Rhizoma increases gastric mucosal blood flow,and improves growth and reparation of gastric mucosa to produce anti-ulcer effect by blockade of 5-TH receptor,and elevating levels of gastrin and trefoil factor in serum and gastric tissues.Atractylodis Rhizoma accelerating gastric emptying and gastrointestinal propellant movement is relative to decreasing release of central corticotropin-releasing factor,and stimulating vagal nerve,and promoting secretion of gastrin and motilin,and inhibiting secretion of vasoactive intestinal peptide,and blocking 5-HT-3receptor,and increasing amount of interstitial cell of Cajal.
5.Analysis on adverse reactions and their related factors in 52 cases of atorvastatin
Drug Evaluation Research 2017;40(3):406-410
Objective To explore the general rules and characteristics of adverse reactions induced by atorvastatin,and to provide reference for clinical rational use of drugs.Method A retrospective analysis was made on the statistics and analysis of the ADR report forms collected in Fujian Changle Hospital from January 2008 to May 2016.Results The adverse reactions induced by atorvastatin were 52 cases.The number of adverse reactions was up to a maximum of hepatobiliary system damage 22 times (37.29%),gastrointestinal system damage 11 times (18.64%),systemic damage 5 times (8.47%),musculoskeletal system damage 5 times (8.47%),myocardium,endocardium,pericardial and valvular damage 4 times (6.78%),auditory and vestibular function damage 4 times (6.78%).Conclusion The clinical application of atorvastatin should be strengthened in order to reduce the occurrence of adverse reactions.
6.Systematic review of tandospirone and buspirone in treatment of patients with generalized anxiety disorder
Xiaodong FAN ; Xingxing XIE ; Chunyan ZHANG ; Wenqiang KONG ; Chunyang ZHOU ; Biao DU
Drug Evaluation Research 2017;40(3):400-405
Objective To evaluate the therapeutic effect and safety of tandospirone and buspirone in the treatment of generalized anxiety disorder.Methods The clinical control study oftandospirone and buspirone in the treatment of generalized anxiety disorder was earched by PubMed,CBM,CNKI,VIP,and Wanfang Data,with deadline from January 2000 to June 2016.Meta-analysis was carried out using RevMan5.0 software to each effect index.Results A total of seven RCTs were included involving 615 patients were identified.Meta-analysis showed that the significant efficiency rate[P=0.34,OR=1.19,95%CI (0.83~1.69)] and HAMA[P=0.80,MD=-0.08,95%CI (-0.72~0.56)] of tandospirone and buspirone had no significant difference.Two groups of adverse drug reactions,dizzy,dry,constipine,insomnia,anorexia,and nausea had no significant difference (P>0.05).Conclusion The efficacy and adverse reaction oftandospirone and buspirone in the treatment of generalized anxiety disorder are fairly.
7.Meta-analysis on Jinlianqingre Effervescent Tablet for acute upper respiratory tract infection in children
Chengliang ZHONG ; Siyuan HU ; Jingfeng LI ; Jianting WU ; Qiang XU
Drug Evaluation Research 2017;40(3):393-399
Objective To systematically review the efficacy and safety of Jinlian Qingre Effervescent Tablet (JQET) compared to Ribavirin for acute upper respiratory tract infection in children.Methods CNKJ,CBM,WanFang Data,VIP,PubMed,EM base,Web of science,and Cochrane Library databases were searched from the date of establishment to December 2016 for all randomized controlled trials (RCTs) and quasi-RCT on the use of JQET in children with acute respiratory infections.Meta-analysis by using Rev Man 5.3.Results A total of seven RCTs involving 782 patients were included,while the group of JQET involving 392 patients,Ribavirin involving 390 patients.The results ofmeta-analysis indicated that the efficacy in Jinlianqingre group was superior to that of Ribavirin control group,such as clinical effectiveness [RR=l.26,95%CI=(1.18,1.34),P<0.000 01],fever subsidence time [MD=-1.54,95%CI (-1.79,-1.30),P<0.000 01],the time of subsided cough [MD=-1.53,95%CI (-1.79,-1.27),P<0.000 01],the disappearance time of pharyngalgia [MD=-1.29,95%CI (-1.88,-0.70),P<0.000 1],and Pharyngeal congestion disappearance time [MD=-2.80,95%CI(-3.11,-2.49),P<0.000 01].The difference was statistically significant.There were three adverse reactions reported in JQET group.Conclusion JQET is superior to the Ribavirin control group in clinical effectiveness,fever subsidence time,time of subsided cough,disappearance time of pharyngalgia,and pharyngeal congestion disappearance time to treat acute upper respiratory tract infection in children.However,these results should be carefully interpreted,and this conclusion has to be further verified by high quality,large scale RCTs.
8.Etelcalcetide: A new drug for secondary hyperparathyroidism of chronic kidney disease
Fei ZHENG ; Yanli ZHANG ; Qian ZHANG ; Ying GONG ; Yuanyuan GU ; Guodong HUA
Drug Evaluation Research 2017;40(3):428-432
Etelcalcetide (ParsabivTM) is a second generation calcimimetic agent newly developed by Amgen,mainly used for the treatment of secondary hyperparathyroidism.Etetcalcetide not only decreases calcium concentration by directly binding with the calcium sensing receptor,but also reduces the parathyroid hormone level.The European Union has approved for chronic kidney disease patients with secondary hyperparathyroidism in dialysis with Etelcalcetide injection.This paper summarized the pharmacological effects,pharmacokinetics,clinical trials,and adverse reaction of Etelcalcetide.
9.Research progress on nucleoside drugs combination used in clinic against chronic hepatitis B
Can CUI ; Lina ZHAO ; Lin WANG
Drug Evaluation Research 2017;40(3):424-427
Hepatitis B is a serious hazard to human health.This paper describes the current clinical use of several nucleoside antiviral drugs combination,and introduces the candidate drugs which are able to effectively inhibit the hepatitis B virus replication in vivo and in vitro in two years,which provides reference for the research and development of new anti-HBV drugs.
10.Anesthetic effect of intravenous anesthesia with propofol, ketamine, and remifentanil for pediatric orchiopexy
Jinwen GAO ; Meiyu LIN ; Jielian HUANG ; Qunfei ZOU
Drug Evaluation Research 2017;40(3):389-392
Objective To discuss the anesthetic effect of iv injection with propofol for pediatric orchiopexy.Methods Totally 80 children who needed orchiopexy were selected,and were divided into two groups randomly.The control group (39 cases) were iv given propofol and ketamine for anesthesia.The observation group (41 cases) were iv given propofol,ketamine,and remifentanil.The anesthetic effect of propofol for pediatric orchiopexy was evaluated by HR,MAP,SpO2,recovery time,dosage of propofol and ketamine,and postoperative adverse reaction.Results Before the injection and injection for 5 min,there was no statistical significance on MAP,HR,and SpO2 between two groups.Pulling the testicles,the MAP and HR in observation group were lower than those in control group (P < 0.05).There was no statistical significance on SpO2.The recovery time of observation group was shorter than that of control group (P < 0.05).And the dosages of propofol and ketamine in observation group were also less than those in control group (P < 0.05).There was no statistical significance on postoperative adverse reaction between two groups.Conclusion The iv anesthesia with propofol has a good anesthetic effect on the pediatric orchiopexy.The anesthesia is stable and has little effect on vital signs,rapid postoperative recovery without increasing adverse reaction,which is worthy of clinical use.